Tocilizumab: Blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders

Drugs of Today

Volumn 42, Issue 9, 2006, Pages 559-576

  Paul Pletzer, Kalanethee ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACR 20; ACR 50; ACR 70; ATLIZUMAB; INTERLEUKIN 5; INTERLEUKIN 6; METHOTREXATE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAPHYLAXIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTHRITIS; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; INFLAMMATORY DISEASE; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN DISEASE; SUBCUTANEOUS TISSUE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INTERLEUKIN-6; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 33750102235     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.9.1025692     Document Type: Review

References (70)

1. Hirano, T., Akira, S., Taga, T., Kishimoto, T. Biological and clinical aspects of interleukin 6. Immunol Today 1990, 11: 443-9.
2. Hirano, T. Interleukin 6 and autoimmunity and plasma cell neoplasias. Res Immunol 1992, 143: 759-63.
3. Akira, S., Taga, T., Kishimoto, T. Interleukin-6 in biology and medicine. Adv Immunol 1993, 54: 1-78.
4. Sehgal, P.B., Greininger, G., Tosato, G. Acute phase and immune responses: Interleukin-6. Ann NY Acad Sci 1989, 557: 1-583.
5. Andus, T., Geiger, T., Hirano, T. et al. Recombinant human B cell stimulatory factor 2(BSF-2/INF-α2) regulates B-fibrinogen and albumin mRNA levels in Fao-9 cell. FEBS Lett 1987, 221: 18-22.
6. Muraguchi, A., Hirano, T., Tang, B. et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988, 67: 332-44.
7. Le, J., Fredrickson, G., Reis, L. et al. Interleukin-2-dependent and interleukin-2-independent pathways of regulation of thymocyte function by interleukin-6. Proc Natl Acad Sci USA 1988, 85: 8643-7.
8. Okada, M., Kitahara, M., Kishimoto, S., Matsuda, T., Hirano, T., Kishimoto, T. BSF-2/IL-6 functions as killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988, 141: 1543-9.
9. Tabibzadeh, S., Kong, Q.F., Babaknia, A., May, L.T. Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. Mol Hum Reprod 1995, 1: 2793-9.
10. Krueger, J.G., Krane, J.F., Carter, D.M., Gottlieb, A.B. Role of growth factors, cytokines and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 1990, 94 (Suppl.): 135S-140S.
11. Yoshizaki, K., Nishimoto, N., Matsumoto, K. et al. Interleukin-6 and expression of its receptor on epidermal keratinocytes. Cytokines 1990, 2: 381-7.
12. Ishibashi, T., Kimura, H., Shikawa, H. et al. Human interleukin-6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 1987, 86: 5953-7.
13. Navarro, S., Devili, N., LeCouedic, J.P. et al. Interleukin-6 and its receptor are expressed by human megakaryocytes: In vitro effects on proliferation and endoreplication. Blood 1991, 77: 461-71.
14. Chiu, C.P., Lee, F., Fero, T.J., Johnson, A., Everitt, J., Malik, A.B. IL-6 is a differentiation factor for M1 and WEHI-3B myeloid leukemic cells. J Immunol 1989, 142: 1909-15.
15. Satoh, T., Nakamura, S., Taga, T. et al. Induction of neuronal differentiation in PC12 cells by B cell stimulatory factor 2/interleukin 6. Mol Cell Biol 1988, 8: 3546-9.
16. Tamura, T., Udagawa, N., Takahashi, N. et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993, 90: 11924-8.
17. Kawano, M., Hirano, T., Matsuda, T. et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332: 83-5.
18. Miki, S., Iwano, M., Miki, Y. et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989, 250: 607-10.
19. Honda, M., Yamamoto, S., Cheng, M. et al. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J Immunol 1992, 148: 2175-80.
20. Scala, G., Ruocco, M.R., Ambrosino, C. et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 1994, 179: 961-71.
21. Yoshizaki, K., Matsuda, T., Nishimoto, N. et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989, 74: 1360-7.
22. Kotake, S., Sato, K., Kim, K.J. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids form rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11: 88-95.
23. Wagge, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., Espevik, T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989, 169: 333-8.
24. Murakami, M., Hibi, M., Nakagawa, N. et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993, 260: 1808-10.
25. Taga, T., Kishimoto, T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15: 797-819.
26. Rose-John, S., Heinrich, P.C. Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J 1994, 300: 281-90.
27. Wendling, D., Racadot, E., Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993, 20: 259-62.
28. Emilie, D., Wijdenes, J., Gisselbrecht, C. et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms. Blood 1994, 84: 2472-9.
29. Sato, K., Tsuchiya, M., Saldanha, J. et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993, 53: 851-6.
30. Nishimoto, N., Kishimoto, T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4: 386-91.
31. Yoshizaki, K., Nishimoto, N., Mihara, M., Kishimoto, T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998, 20: 247-59.
32. Houssiau, F.A., Devogelaer, J.P., Van Damme, J., De Deuxchaisies, C.N., Van Snick, J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. Arthritis Rheum 1988, 31: 784-8.
33. Hirano, T., Matsuda, T., Turner, M. et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988, 18: 1797-801.
34. Choy, E.H., Isenberg, D.A., Garrood, T. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46: 3143-50.
35. Nishimoto, N., Yoshizaki, K., Maeda, K. et al. Toxicity, pharmacokinetics and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003, 30: 1426-35.
36. Maini, R.N., Taylor, P.C., Pavelka, K., CHARISMA study group. Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). Arthritis Rheum 2003, 48 (Suppl.): S652: 1704.
37. Maini, R., CHARISMA study group. A double-blind, randomized, parallel-group, controlled, dose-ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003b, 62 (Suppl.): 1-64.
38. Nishimoto, N., Yoshizaki, K., Miyasaka, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004b, 50: 1761-9.
39. Nishimoto, N., Hashimoto, J., Miyasaka, N. et al. Blocking interleukin-6 (IL-6) by tocilizumab (a humanized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis (RA): Evidence from an X-ray reader-blinded randomized controlled trial. Presented at the Annual Scientific Meeting of the American College of Rheumatology, San Diego 2005, Abst. L27.
40. Nishimoto, N., Miyasaka, N., Yamamoto, K. et al. Efficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: Results from a 24-week double-blind phase III study. Ann Rheum Dis 2006, 65 (Suppl. II): 59, Abst. OP0020.
41. Castleman, B., Iverson, L., Menéndez, V.P. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956, 9: 822-30.
42. Keller, A.R., Hochholzer, L., Castleman, B. Hyalinevascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972, 29: 670-83.
43. Nishimoto, N., Sasai, M., Shima, Y. et al. Improvement in Castleman's disease by humanized anti-IL-6 receptor antibody therapy. Blood 2000b, 95: 56-61.
44. Nishimoto, N., Kanakura, Y., Aozasa, K., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106: 2627-32.
45. Shanahan, F. Crohn's disease. Lancet 2002, 359: 62-9.
46. Targan, S.R., Hanauer, S.B., van Deventer, S.J. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337: 1029-35.
47. Mitsuyama, K., Toyonaga, A., Sasaki, E. et al. Soluble interleukin-6 receptors in inflammatory bowel disease: Relation to circulating interleukin-6. Gut 1995, 36: 45-9.
48. Hosokawa, T., Kusugami, K., Ina, K. et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 1999, 14: 987-96.
49. Ito, H., Takazoe, M., Fukuda, Y. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004, 126: 989-96.
50. Petty, R.E., Southwood, T.R., Manners, P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004, 31: 390-2.
51. de Benedetti, F., Massa, M., Robbioni, P., Ravelli, A., Burgio, G.R., Martini, A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34: 1158-63.
52. Rooney, M., David, J., Symons, J., Di Giovine, F., Varsani, H., Woo, P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995, 34: 454-60.
53. Prieur, A.M., Roux-Lombard, P., Dayer, J.M. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rhum Engl Ed 1996, 63: 163-70.
54. Yokota, S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003, 15: 581-6.
55. Yokota, S., Miyamae, T., Imagawa, T. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005, 52: 818-25.
56. Woo, P., Wilkinson, N., Prieur, A.M. et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005, 7: R1281-8.
57. Yokota, S., Imagawa, T., Mori, M. et al. A multicenter, randomized, double-blind, placebo-controlled study of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in children with systemic juvenile idiopathic arthritis. Ann Rheum Dis 2006, 65 (Suppl. II): 59, Abst. OP0021.
58. Bywaters, E.G. Still's disease in the adult. Ann Rheum Dis 1971, 30: 121-33.
59. Iwamoto, M., Nara, H., Hirata, D., Minota, S., Nishimoto, N., Yoshizaki, K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002, 46: 3388-9.
60. Barcellini, W., Clerici, G., Montesano, R. et al. In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: Effect of mitogen and cytokine stimulation. Br J Haematol 2000, 111: 452-60.
61. Kunitomi, A., Konaka, Y., Yagita, M., Nishimoto, N., Kishimoto, T., Takatsuki, K. Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia. Int J Hematol 2004, 80: 246-9.
62. Lipsky, P.E., van der Heijde, D.M., St Clair, E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343: 1594-602.
63. Bresnihan, B., Alvaro-Gracia, J.M., Cobby, M. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41: 2196-204.
64. Choy, E.H., Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344: 907-16.
65. Ettinger, W.H., Varma, V.K., Sorci-Thomas, M. et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 1994, 14: 8-13.
66. Murthy, S., Mathur, S., Bishop, W.P., Field, E.J. Inhibition of apolipoprotein B secretion by IL-6 is mediated by EGF or an EGF-like molecule in CaCo-2 cells. J Lipid Res 1997, 38: 206-16.
67. Gierens, H., Nauck, M., Roth, M. et al. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol 2000, 20: 1777-83.
68. Grunfeld, C., Feingold, K.R. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992, 327: 329-37.
69. Testa, M., Yeh, M., Lee, P. et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996, 28: 964-71.
70. Sezgin N., Sezgin A.T., Gullu H. et al. Decreased serum lipoprotein levels as a guide for clinical severity in patients with idiopathic dilated cardiomyopathy. Tohoku J Exp Med 2005, 206: 219-24.